This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands
by Zacks Equity Research
OPKO Health reports wider-than-expected second-quarter 2025 loss and revenue decline, but gross margin expands and product sales remain stable.
TMDX Stock Gains Post Q2 Earnings & Revenue Beat, Margins Up
by Zacks Equity Research
TransMedics stock jumps 10.5% as Q2 EPS beats by 91.7%, revenue rises 37.7%, and operating margin expands 1230 basis points.
GEHC vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
GEHC vs. BSX: Which Stock Is the Better Value Option?
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb
by Zacks Equity Research
RMD tops Q4 earnings and revenue estimates with double-digit growth, rising margins and strong global device demand.
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised
by Zacks Equity Research
Glaukos' second-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
CONMED Q2 Earnings & Revenues Beat Estimates, 2025 Outlook Raised
by Zacks Equity Research
CNMD reports solid second-quarter results, driven by improving sales across both segments.
Merit Medical Q2 Earnings Beat Estimates, Gross Margin Expands
by Zacks Equity Research
MMSI beats second-quarter 2025 earnings estimates as gross margin expands and strong U.S. and Cardiovascular sales drive revenue growth.
CVS Stock Up on Q2 Earnings & Revenue Beat, '25 EPS View Raised
by Zacks Equity Research
CVS Health beats on Q2 earnings and raises 2025 EPS outlook, lifting shares nearly 8% on strong segment growth and margin gains.
ALGN Stock Falls on Q2 Earnings and Revenue Miss, Margins Down
by Zacks Equity Research
Align Technology tumbles 34.2% after Q2 earnings and revenues miss estimates as Clear Aligner sales drop and margins tighten further.
Hologic Stock Falls Despite Q3 Earnings and Revenue Beat, Margins Down
by Zacks Equity Research
HOLX posts better-than-expected Q3 results, but margin contraction and regional headwinds pressure investor sentiment.
GE HealthCare Q2 Earnings & Sales Beat Estimates, Net Margin Rises
by Zacks Equity Research
GEHC's second-quarter results reflect strength in the Imaging and Pharmaceutical Diagnostics segments. The bottom line improves with better pricing.
Ecolab Stock Down in Pre-Market Post Q2 Earnings Miss, Margins Expand
by Zacks Equity Research
ECL stock dips in pre-market despite second-quarter 2025 earnings growth and margin expansion, as EPS misses estimates by a penny.
WGS Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 Sales View
by Zacks Equity Research
GeneDx reports strong Q2 results with record revenues and surging profits. A raised 2025 sales outlook fuels a 26% stock jump.
Top Stock Reports for Microsoft, SAP & AMD
by Mark Vickery
MSFT, SAP, and AMD are driving growth with cloud, AI, and chip innovation despite competitive and cost headwinds.
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Amneal Pharmaceuticals (AMRX) and Boston Scientific (BSX) have performed compared to their sector so far this year.
ISRG's Gross Margin Falls on Product Transition and Trade Pressures
by Indrajit Bandyopadhyay
Intuitive Surgical's Q2 gross margin declines to 67.9% as product mix shifts, new facility costs and tariffs weigh on profitability.
Integer Holdings Q2 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
ITGR posts strong second-quarter revenue growth, but EPS misses estimate despite solid segment momentum.
Company News for Jul 24, 2025
by Zacks Equity Research
Companies In The News Are: T, TMO, GD, BSX.
Boston Scientific Beats on Q2 Earnings, Raises 2025 View, Stock Up
by Zacks Equity Research
BSX beats Q2 estimates, raises full-year outlook as Cardiovascular sales surge and global revenues climb 22.8%.
Thermo Fisher Q2 Earnings & Revenues Beat, Stock Up in Pre-Market
by Zacks Equity Research
TMO tops Q2 estimates as new product launches and solid segment growth fuel revenue gains despite margin pressure.
Boston Scientific (BSX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ISRG Stock Gains on Q2 Earnings & Sales Beat, Gross Margin Contracts
by Zacks Equity Research
Intuitive Surgical's second-quarter results reflect a healthy demand for procedures on higher system utilization. However, tariffs lead to a decline in the gross margin outlook.
Boston Scientific (BSX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of +4.17% and +3.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Molina to Report Q2 Earnings: Healthy Revenues, Weak Pulse on Earnings
by Zacks Equity Research
MOH's Q2 revenues are set to rise nearly 10%, but rising costs cloud its profit outlook.